MED-C's Groundbreaking NGS Registry Gets IRB Approval

WASHINGTON, Sept. 12, 2016 /PRNewswire/ -- The White House Cancer Moonshot has challenged medicine to speed progress in battling America's No. 2 killer. A nonprofit upstart soon will start making significant contributions toward this goal after approval of its study this week by a national institutional review board (IRB).

This approval will allow the Molecular Evidence Development Consortium (MED-C) to launch its N1 Registry, expected to become the largest and most complete openly available cancer database including next-generation sequencing (NGS) data accompanied by clinical outcomes.

"With IRB approval we can proceed to take the final steps toward launching the N1 Registry," said Dr. Dane J. Dickson, M.D., and CEO of MED-C. "We are confident our efforts will contribute significantly to the Moonshot's challenges to enhance data sharing and improve clinical trials processes."

MED-C's registry will be overseen by an investigator core of 15 internationally recognized hematology and oncology leaders and closely monitored by key industry organizations as a potential disruptive innovation in precision medicine.

A summary of the protocol is recorded on ClinicalTrials.gov, entitled "Patients Diagnosed with Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A MED-C Observational Registry (N1)"

MED-C is a nonprofit organization aiming to unify all key medical stakeholders to advance precision medicine through its N1 Registry that will contain standardized, high-quality, next-generation sequencing combined with clinical outcomes.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE MED-C